DEDICATED TO PROVIDING UNCOMMON EXPERTISE FOR YOUR ONCOLOGY CLINICAL TRIAL
Our award-winning, specialized early phase oncology CRO team helps emerging and established biopharma, biotech and pharmaceutical companies accelerate the advancement of early phase compounds through clinical testing.
YOUR CANCER THERAPY SHOWS PROMISE. GET ON YOUR WAY TO FDA APPROVAL FASTER AND EASIER WITH WORLDWIDE AS YOUR ONCOLOGY CRO.
The competitive landscape for oncology research is at an all-time high, and trial designs are increasing in complexity. Recent reports indicate that the success rate of investigational compounds approved for clinical use in cancer is the lowest among all diseases, and the likelihood of approval for investigational oncology drugs tested in Phase I trials is only 6.7 percent.1 Who you select as your CRO partner can have a significant impact on the success and/or failure of your clinical study and program. Who can you trust to help you with your development journey?
YOU’RE MORE THAN A MOLECULE TO WORLDWIDE.
OUR MEDICAL, SCIENTIFIC AND OPERATIONS EXPERTS TAKE YOUR CHALLENGE PERSONALLY.
With Worldwide, you get the best of both worlds: A specialized CRO with global coverage. We’re a full-service, midsized CRO with therapeutic experts who have earned reputations for taking on the most complex and challenging cancer research studies. We offer a global footprint – without the hefty price tag and cookie-cutter approach you get from large, consolidating CROs.
1 Pharmaceutical Research and Manufacturers of America. Medicines in development: Cancer [online], 2014. Available at https://www.phrma.org/sites/default/files/pdf/2014-cancer-report.pdf.